CING Stock Forecast 2025-2026
Distance to CING Price Targets
CING Price Momentum
10 Quality Stocks Worth Considering Now
Researching Cingulate (CING) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CING and similar high-potential opportunities.
Latest CING Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, CING has a bullish consensus with a median price target of $16.00 (ranging from $8.00 to $62.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $4.24, the median forecast implies a 277.4% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Raghuram Selvaraju at HC Wainwright & Co., suggesting a 88.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CING Analyst Ratings
CING Price Target Range
Latest CING Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CING.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $20.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $20.00 |
| Jan 10, 2025 | Roth MKM | Boobalan Pachaiyappan | Buy | Initiates | $12.00 |
| Nov 20, 2024 | Maxim Group | Naz Rahman | Buy | Upgrade | $0.00 |
| Jan 5, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $8.00 |
| Dec 22, 2023 | Laidlaw & Co. | Yale Jen | Hold | Downgrade | $0.00 |
| Dec 19, 2023 | Maxim Group | Naz Rahman | Hold | Downgrade | $0.00 |
| Dec 18, 2023 | Maxim Group | Naz Rahman | Hold | Downgrade | $0.00 |
| Sep 26, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $3.50 |
| Jan 17, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $5.50 |
| Nov 22, 2022 | Maxim Group | Naz Rahman | Buy | Initiates | $3.00 |
| Jan 20, 2022 | Laidlaw & Co. | Yale Jen | Buy | Initiates | $8.50 |
| Jan 11, 2022 | Aegis Capital | Buy | Initiates | $0.00 |
Cingulate Inc. (CING) Competitors
The following stocks are similar to Cingulate based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cingulate Inc. (CING) Financial Data
Cingulate Inc. has a market capitalization of $15.47M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -5,305.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cingulate Inc. (CING) Business Model
About Cingulate Inc.
Develops treatments for neurological and psychiatric disorders.
Cingulate Inc. generates revenue by developing and commercializing innovative treatments aimed at neurological and psychiatric disorders, specifically focusing on ADHD. Utilizing its proprietary Precision Timed Release (PTR) platform, the company enhances medication timing and effectiveness, which can lead to better patient outcomes and potentially higher market demand for its products.
Cingulate's commitment to advancing mental health treatment extends beyond ADHD to other neurological conditions, positioning the company as a transformative entity within the biopharmaceutical industry. Its focus on addressing unmet medical needs and optimizing treatment protocols aligns with broader healthcare trends aimed at improving patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Dr. Shane J. Schaffer Pharm.D.
Country
United States
IPO Year
2021
Website
www.cingulate.comCingulate Inc. (CING) Latest News & Analysis
CTx-2103 may become the first once-daily formulation of buspirone, targeting the $5.5 billion U.S. anxiety market and the $11.6 billion global market.
CTx-2103's potential as a once-daily buspirone could capture significant market share in the lucrative anxiety market, impacting revenues and stock valuations for involved companies.
An in-person FDA meeting is set for April 2, with a new drug application expected by mid-2025. The company has increased working capital by $17.5 million, extending cash runway into Q4.
The FDA meeting and extended cash runway signal potential drug approval, reducing financial risk and enhancing investor confidence in future growth.
Cingulate Inc. (NASDAQ: CING) has secured $5 million in a financing transaction with an accredited investor to support its drug delivery platform and product pipeline.
Cingulate Inc.'s $5 million financing strengthens its financial position, enabling further development of its drug pipeline, which can enhance future revenue potential and stock performance.
The company plans to submit a New Drug Application (NDA) for its lead ADHD asset, CTx-1301, by mid-2025.
The mid-2025 NDA submission for CTx-1301 signals potential revenue growth and market entry for the ADHD drug, impacting company valuation and investor confidence.
Cingulate Inc. CEO Shane J. Schaffer discussed the company's ADHD treatment CTx-1301 and commercialization plans on the Big Biz Show, highlighting its proprietary PTR™ drug delivery technology.
Cingulate Inc.'s CEO discussing Phase 3 asset CTx-1301 and commercialization plans signals potential revenue growth and market expansion, influencing investor sentiment and stock performance.
The company has raised an additional $10 million in capital, enhancing its balance sheet.
The $10 million raised enhances the company's financial stability, potentially increasing investor confidence and supporting future growth initiatives.
Frequently Asked Questions About CING Stock
What is Cingulate Inc.'s (CING) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Cingulate Inc. (CING) has a median price target of $16.00. The highest price target is $62.00 and the lowest is $8.00.
Is CING stock a good investment in 2025?
According to current analyst ratings, CING has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CING stock?
Wall Street analysts predict CING stock could reach $16.00 in the next 12 months. This represents a 277.4% increase from the current price of $4.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cingulate Inc.'s business model?
Cingulate Inc. generates revenue by developing and commercializing innovative treatments aimed at neurological and psychiatric disorders, specifically focusing on ADHD. Utilizing its proprietary Precision Timed Release (PTR) platform, the company enhances medication timing and effectiveness, which can lead to better patient outcomes and potentially higher market demand for its products.
What is the highest forecasted price for CING Cingulate Inc.?
The highest price target for CING is $62.00 from at , which represents a 1,362.3% increase from the current price of $4.24.
What is the lowest forecasted price for CING Cingulate Inc.?
The lowest price target for CING is $8.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 88.7% increase from the current price of $4.24.
What is the overall CING consensus from analysts for Cingulate Inc.?
The overall analyst consensus for CING is bullish. Out of 5 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are CING stock price projections?
Stock price projections, including those for Cingulate Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.